Skip to main content
. 2018 Dec 18;58(7):921–927. doi: 10.2169/internalmedicine.1462-18

Figure 1.

Figure 1.

Relapse-free survival curves in all patients for each clinicopathological factors. (A) All pulmonary pleomorphic carcinoma patients (n=35); (B) according to lymph node metastasis; (C) according to tumor size; (D) according to the PD-L1 expression; (E) according to parietal-pleural invasion; (F) according to tumor stage.